Literature DB >> 7944692

Resection of lung cancer is justified in high-risk patients selected by exercise oxygen consumption.

G L Walsh1, R C Morice, J B Putnam, J C Nesbitt, M J McMurtrey, M B Ryan, J M Reising, K M Willis, J D Morton, J A Roth.   

Abstract

The medical criteria for inoperability have been difficult to define in patients with lung cancer. Sixty-six patients with non-small cell lung cancer and radiographically resectable lesions were evaluated prospectively in a clinical trial. The patients were considered by cardiac or pulmonary criteria to be high risk for pulmonary resection. If exercise testing revealed a peak oxygen uptake of 15 mL.kg-1.min-1 or greater, the patient was offered surgical treatment. Of the 20 procedures performed, nine were lobectomies, two were bilobectomies, and nine were wedge or segmental resections. All patients were extubated within 24 hours and discharged within 22 days after operation (median time to discharge, 8 days). There were no deaths, and complications occurred in 8 (40%) of the 20 patients. Five patients whose peak oxygen uptake was lower than 15 mL.kg-1.min-1 also underwent surgical intervention; there was one death. Thirty-four patients whose peak oxygen uptake was less than 15 mL.kg-1.min-1 and 7 who declined operation underwent radiation therapy alone (35 patients) or radiation therapy and chemotherapy (6 patients). There were no treatment-related deaths, and the morbidity rate was 12% (5/41). The median duration of survival was 48 +/- 4.3 months for the patients treated surgically and 17 +/- 2.7 months for those treated medically (p = 0.0014). We conclude that a subgroup of patients who would be considered to have inoperable disease by traditional medical criteria can be selected for operation on the basis of oxygen consumption exercise testing. There is a striking survival benefit to an aggressive surgical approach in these patients.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7944692     DOI: 10.1016/0003-4975(94)90731-5

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  7 in total

1.  BTS guidelines: guidelines on the selection of patients with lung cancer for surgery.

Authors: 
Journal:  Thorax       Date:  2001-02       Impact factor: 9.139

Review 2.  Risk assessment of lung resection for lung cancer according to pulmonary function: republication of systematic review and proposals by guideline committee of the Japanese association for chest surgery 2014.

Authors:  Noriyoshi Sawabata; Takashi Nagayasu; Yoshihisa Kadota; Taichiro Goto; Hiroyoshi Horio; Takeshi Mori; Shinichi Yamashita; Akinori Iwasaki
Journal:  Gen Thorac Cardiovasc Surg       Date:  2014-09-27

3.  Effect of therapeutic hyperoxia on maximal oxygen consumption and perioperative risk stratification in chronic obstructive pulmonary disease.

Authors:  Hilary M Womble; Richard M Schwartzstein; Richard P Johnston; David H Roberts
Journal:  Lung       Date:  2012-01-17       Impact factor: 2.584

4.  Effect of thoracotomy and lung resection on exercise capacity in patients with lung cancer.

Authors:  A M Nugent; I C Steele; A M Carragher; K McManus; J A McGuigan; J R Gibbons; M S Riley; D P Nicholls
Journal:  Thorax       Date:  1999-04       Impact factor: 9.139

5.  Clinical relevance of decreased oxygen saturation during 6-min walk test in preoperative physiologic assessment for lung cancer surgery.

Authors:  Tatsuo Nakagawa; Naohisa Chiba; Masao Saito; Yasuto Sakaguchi; Shinya Ishikawa
Journal:  Gen Thorac Cardiovasc Surg       Date:  2014-05-09

6.  Oxygen Uptake Efficiency Slope and Prediction of Post-operative Morbidity and Mortality in Patients with Lung Cancer.

Authors:  Sertaç Yakal; Sevtün Sofyalı; Berker Özkan; Safinaz Yıldız; Alper Toker; Erdem Kasikcioglu
Journal:  Lung       Date:  2018-01-18       Impact factor: 2.584

7.  Variations in the vascular endothelial growth factor pathway predict pulmonary complications.

Authors:  Jae Y Kim; Michelle A T Hildebrandt; Xia Pu; Yuanqing Ye; Arlene M Correa; Ara A Vaporciyan; Xifeng Wu; Jack A Roth
Journal:  Ann Thorac Surg       Date:  2012-07-12       Impact factor: 4.330

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.